Teva’s Long-Acting Olanzapine Injection Clears EMA Review Hurdle
Event summary
- The European Medicines Agency (EMA) accepted Teva’s Marketing Authorization Application for TEV-‘749, a long-acting injectable olanzapine for schizophrenia, on May 21, 2026.
- TEV-‘749 is designed for subcutaneous administration every four weeks, leveraging Medincell’s SteadyTeq™ technology.
- The submission is supported by the Phase 3 SOLARIS study, demonstrating efficacy and safety consistent with oral olanzapine.
- If approved, TEV-‘749 would address treatment adherence challenges in schizophrenia, a condition affecting 0.3–1.5% of Europe’s population.
The big picture
Teva’s submission of TEV-‘749 to the EMA aligns with its strategic shift toward innovative treatments in neuroscience. The move comes as long-acting injectables gain traction in managing chronic conditions like schizophrenia, where adherence remains a critical challenge. Success here could bolster Teva’s position in the mental health sector, but competition from established players and regulatory hurdles remain key hurdles.
What we're watching
- Regulatory Timeline
- The pace at which the EMA reviews TEV-‘749 will determine its commercialization timeline in Europe.
- Market Differentiation
- Whether TEV-‘749 can carve out a niche in a competitive schizophrenia treatment landscape dominated by oral and injectable alternatives.
- Execution Risk
- Teva’s ability to scale production and distribution of TEV-‘749 while managing its existing portfolio under its Pivot to Growth strategy.
Related topics